Study guide

17.2 Neoplasia Principles & Tumor Biology

NBME Comprehensive Basic Science Examination CBSE

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Navigation

1.1 Current Exam Facts & Administration 1.2 Content Blueprint & Physician Tasks 1.3 Scoring, Score Reports & Step 1 Readiness

2 Human Development

2.1 Embryology & Congenital Development Patterns 2.2 Normal Age-Related Findings & Well-Patient Care

3 Blood & Hematologic Disease

3.1 Hematopoiesis, RBC Disorders & Anemias 3.2 Hemostasis, Thrombosis & Coagulopathies 3.3 WBC Disorders, Leukemia & Lymphoma Mechanisms

4 Immune System

4.1 Innate & Adaptive Immunity Mechanisms 4.2 Hypersensitivity, Autoimmunity & Immunodeficiency 4.3 Transplant Immunology & Immune Pharmacology

5 Nervous System Anatomy & Disease

5.1 Neuroanatomy Localization & Pathways 5.2 Stroke, Infection, Demyelination & Trauma 5.3 Seizures, Movement Disorders & Neurodegeneration 5.4 Special Senses: Eye & Ear Mechanisms

6 Behavioral Health

6.1 Psychiatric Disorders & Diagnostic Patterns 6.2 Psychopharmacology Mechanisms 6.3 Neurotransmitters, Learning & Behavioral Science

7 Musculoskeletal System

7.1 Bone Physiology, Fracture Healing & Bone Pathology 7.2 Joint Disease, Rheumatology & Connective Tissue 7.3 Muscle, NMJ & Peripheral Nerve Disorders

8 Skin & Soft Tissue

8.1 Dermatopathology High-Yield Lesions 8.2 Inflammation, Wound Healing & Soft-Tissue Infection

9 Cardiovascular Pathophysiology

9.1 Cardiac Cycle, Hemodynamics & Murmurs 9.2 Ischemic Heart Disease & Cardiomyopathy 9.3 Congenital & Valvular Heart Disease 9.4 Vascular Pathology & Hypertension

10 Cardiovascular Pharmacology

10.1 Antihypertensives, Heart Failure & Antiarrhythmics 10.2 Antiplatelets, Anticoagulants & Lipid Drugs

11 Respiratory System

11.1 Pulmonary Mechanics & Gas Exchange 11.2 Obstructive, Restrictive & Vascular Lung Disease 11.3 Pulmonary Infections, Neoplasms & Respiratory Pharmacology

12 Renal Physiology & Electrolytes

12.1 Nephron Transport & Renal Physiology 12.2 Electrolyte Disorders 12.3 Acid-Base Physiology & Compensation

13 Renal Pathology

13.1 Glomerular Disease Mechanisms 13.2 Tubulointerstitial, Vascular & Stone Disease

14 Gastrointestinal System

14.1 GI Physiology, Motility & Digestion 14.2 Esophagus, Stomach & Intestinal Pathology 14.3 Liver, Biliary Tree & Pancreas 14.4 GI Microbiology, Nutrition & Malabsorption

15 Endocrine System

15.1 Hormone Signaling & Hypothalamic-Pituitary Axes 15.2 Thyroid & Parathyroid Disease 15.3 Adrenal Disorders & Steroid Pharmacology 15.4 Diabetes, Glucose Homeostasis & Metabolic Syndrome

16 Reproductive System

16.1 Male & Female Reproductive Physiology 16.2 Pregnancy, Placenta & Developmental Toxicology 16.3 Reproductive Pathology & Hormone-Related Neoplasia

17 Multisystem Processes & Disorders

17.1 Cell Injury, Inflammation & Repair 17.2 Neoplasia Principles & Tumor Biology 17.3 Infection, Sepsis & Multisystem Microbial Disease 17.4 Genetics, Inborn Errors & Environmental Toxicology

18 Biostatistics & Epidemiology

18.1 Study Design, Bias & Causation 18.2 Diagnostic Test Metrics & Screening 18.3 Epidemiology Measures & Population Health

19 Social Sciences & Communication

19.1 Ethics Principles & Decision-Making Capacity 19.2 Communication Skills & Difficult Conversations 19.3 Professionalism, Systems & Practice-Based Learning

20 Integrated Disciplines Capstone

20.1 High-Yield Microbiology Anchors Across Systems 20.2 High-Yield Biochemistry & Molecular Mechanisms 20.3 Integrated Pharmacology Strategy & Exam-Day Execution

17.2 Neoplasia Principles & Tumor Biology

Key Takeaways Explain This Topic AI

Benign tumors are usually well differentiated, slow-growing, circumscribed, and noninvasive; malignant tumors invade, may metastasize, and show anaplasia/high mitotic activity.

Nomenclature: -oma often benign (exceptions: melanoma, lymphoma, mesothelioma, seminoma); carcinoma = epithelial malignancy; sarcoma = mesenchymal; dysplasia and CIS are preinvasive; invasion breaches basement membrane.

Carcinogenesis is multistep accumulation of oncogene activation (RAS, MYC, BCR-ABL, HER2) and tumor-suppressor loss (p53, Rb, APC, BRCA, NF1/2, VHL, WT1); DNA repair defects (HNPCC/MMR, xeroderma/NER, BRCA/HR) raise mutation burden.

Grade reflects differentiation/histologic aggression; stage reflects anatomic extent (TNM) and usually drives prognosis more than grade alone.

High-yield markers and paraneoplastic syndromes link tumors to clinical clues (AFP, hCG, PSA, CEA, CA-19-9, CA-125; PTHrP, ACTH, EPO, Lambert-Eaton); cachexia is TNF/IL-6–driven wasting.

Last updated: August 2026

17.2 Neoplasia Principles & Tumor Biology

Quick Answer: Benign = localized, well differentiated; malignant = invade ± metastasize. Multistep hits activate oncogenes (RAS, MYC, BCR-ABL, HER2) and inactivate suppressors (p53, Rb, APC, BRCA…). Grade = histology; stage = spread. Markers and paraneoplastics fingerprint tumors; cachexia is cytokine-driven.

Tumor biology is core multisystem content: every organ system recycles the same principles. CBSE stems mix nomenclature, genetics, grade/stage logic, and paraneoplastic clues—master the framework once and reuse it everywhere.

Benign vs Malignant Features

A neoplasm is a clonal proliferation with partial or complete escape from normal growth control. Behavior distinguishes benign from malignant more than any single microscopic trait.

Benign tumors grow expansively, often with a capsule or clear border, remain localized, and closely resemble the tissue of origin ( well differentiated ). Mitotic figures are few and normal. They can still kill by location (e.g., meningioma compressing brain, atrial myxoma obstructing flow) or hormone production (adrenal adenoma).

Malignant tumors invade adjacent tissue, destroy architecture, and may metastasize . They show variable differentiation down to anaplasia (loss of differentiation): pleomorphism, hyperchromasia, high N/C ratio, atypical mitoses, loss of polarity. Growth is often rapid with necrosis when vascular supply lags. Metastasis is the definitive malignant property, though not every cancer has metastasized at diagnosis.

  • Feature Benign Malignant
  • Differentiation Usually well Variable; may be anaplastic
  • Growth rate Slow Often faster
  • Borders Circumscribed ± capsule Infiltrative
  • Invasion Absent Present
  • Metastasis Never Possible
  • Mitoses Rare, normal May be numerous/atypical
  • Nomenclature

Suffix -oma often denotes a benign tumor (adenoma, lipoma, chondroma, fibroma). Critical malignant exceptions that sound benign: melanoma , lymphoma , mesothelioma , seminoma , and sometimes “hepatoma” used loosely for HCC—prefer precise names.

Carcinoma = epithelial malignancy (adeno-, squamous cell, transitional/urothelial). Sarcoma = mesenchymal malignancy (osteo-, lipo-, leiomyo-, rhabdomyo-). Blastoma = primitive “small round blue cell” tumors of childhood (neuroblastoma, nephroblastoma/Wilms, retinoblastoma). Teratomas contain multiple germ layers; mature ovarian teratoma is usually benign, immature teratoma can be malignant.

Hamartoma is disorganized but mature tissue indigenous to the site (not a true neoplasm in the strict clonal sense for exams, though some are clonal). Choristoma is normal tissue in an abnormal location (heterotopia).

Dysplasia, CIS, Invasion, Metastasis

Dysplasia is disordered growth with cytologic atypia, often in epithelium (cervix, colon polyps, Barrett esophagus). It may be reversible if the driver is removed (e.g., smoking cessation for bronchial dysplasia) but can progress.

Carcinoma in situ (CIS) is full-thickness dysplastic epithelium without basement membrane invasion. Risk of progression is high; treatment is local because metastasis has not occurred.

Invasion breaches the basement membrane into stroma—first step of malignancy for epithelial tumors. Proteases (MMPs), loss of E-cadherin (cell-cell adhesion), and epithelial–mesenchymal transition programs facilitate invasion.

Metastasis routes:

Lymphatic — carcinomas commonly to regional nodes first.

Hematogenous — sarcomas preferentially; also late carcinomas; liver and lung are common filters; renal cell and hepatocellular invade veins early.

Seeding of body cavities — ovarian carcinoma on peritoneum; medulloblastoma via CSF.

  • Step Key concept
  • Dysplasia Atypia, may reverse
  • CIS Full thickness, no invasion
  • Invasion Through basement membrane
  • Metastasis Discontinuous secondary implants
  • Multistep Carcinogenesis

Cancer requires multiple mutations and epigenetic changes accumulated over time. The Vogelstein adenoma–carcinoma sequence in colon is the teaching prototype: APC loss (early adenoma) → KRAS activation → further hits → p53 loss (carcinoma). Field cancerization explains multiple primary tumors in chronically injured mucosa (e.g., smoking airway).

Initiators cause permanent DNA damage; promoters drive proliferation of initiated clones without necessarily being mutagenic alone (hormones, chronic inflammation). Complete carcinogens do both. Viral oncogenesis (HPV E6/E7 → p53/Rb degradation; EBV; HBV/HCV → chronic injury ± viral integration; HTLV-1) and bacterial drivers (H. pylori → gastric adenocarcinoma and MALT lymphoma) are high-yield.

Oncogenes vs Tumor Suppressors

Oncogenes are activated versions of proto-oncogenes; one hit (gain of function) can drive growth. Mechanisms: point mutation, amplification, translocation.

  • Oncogene Mechanism / product Classic associations
  • RAS (KRAS, NRAS, HRAS) GTP-binding; stuck “on” Pancreas, colon, lung, many others
  • MYC Transcription factor; amplification/translocation Burkitt t(8;14), neuroblastoma N-MYC amp
  • BCR-ABL t(9;22) fusion tyrosine kinase CML, some ALL
  • HER2 (ERBB2) Receptor tyrosine kinase amplification Breast cancer subset; trastuzumab target
  • BCL2 Anti-apoptosis; t(14;18) Follicular lymphoma
  • RET RTK mutations/rearrangements MEN2, papillary thyroid
  • CDK4 / cyclin D Cell-cycle push Various

Tumor suppressor genes normally restrain growth or repair DNA; both alleles typically must be lost (two-hit hypothesis). Knudson’s model for retinoblastoma is classic.

  • Suppressor Function Associations
  • p53 (TP53) DNA damage → arrest/apoptosis; “guardian” Most human cancers; Li-Fraumeni
  • Rb G1/S checkpoint (binds E2F) Retinoblastoma, osteosarcoma; HPV E7
  • APC Wnt/β-catenin regulation FAP, sporadic colon cancer
  • BRCA1/2 Homologous recombination repair Hereditary breast/ovarian
  • NF1 RAS-GAP Neurofibromatosis 1
  • NF2 Merlin NF2, schwannomas, meningiomas
  • VHL HIF ubiquitination VHL syndrome; clear cell RCC
  • WT1 Transcription factor Wilms tumor
  • PTEN PI3K–AKT brake Cowden; many sporadic cancers
  • DNA Repair Defects

Failure to fix DNA raises mutation rate and cancer risk.

  • Defect Pathway Syndrome / cancers
  • Mismatch repair (MLH1, MSH2, etc.) Microsatellite instability HNPCC / Lynch → colon, endometrium, others
  • Nucleotide excision repair UV dimer repair Xeroderma pigmentosum → skin cancers
  • Homologous recombination Double-strand break repair BRCA1/2 → breast, ovary, prostate, pancreas
  • Nonhomologous end joining / ATM DSB response Ataxia-telangiectasia → lymphoma/leukemia

Microsatellite instability-high tumors have distinct morphology and immunotherapy considerations in advanced care, but for CBSE the core is mechanism + organ risk.

Grade vs Stage

Grade evaluates histologic differentiation and mitotic activity (well / moderate / poor / anaplastic, or numeric systems like Gleason for prostate, Nottingham for breast). Higher grade usually means more aggressive biology.

Stage maps anatomic extent: primary tumor size/invasion ( T ), regional nodes ( N ), distant metastasis ( M )—TNM system. Stage generally predicts prognosis better than grade and guides treatment intensity. Always separate “how ugly under the microscope” (grade) from “how far has it gone” (stage).

Tumor Markers (High-Yield)

Markers aid diagnosis, monitoring, and sometimes screening context—not stand-alone proof of cancer.

  • Marker Associations
  • PSA Prostate (also BPH/prostatitis)
  • CEA Colorectal, pancreatic, others; smoking elevates baseline
  • AFP HCC, yolk sac tumor
  • β-hCG Choriocarcinoma, some germ cell tumors
  • CA-125 Ovarian epithelial
  • CA-19-9 Pancreaticobiliary
  • Calcitonin Medullary thyroid carcinoma
  • Chromogranin / synaptophysin Neuroendocrine tumors
  • S-100 / HMB-45 / Melan-A Melanoma lineage
  • Alkaline phosphatase Bone mets / obstruction (nonspecific)
  • Paraneoplastic Syndromes and Cachexia

Paraneoplastic syndromes are remote effects not explained by local invasion or hormones native to the tissue in a physiologic way (or ectopic hormone production).

  • Syndrome Mediator Classic tumors
  • Hypercalcemia PTHrP Squamous cell lung, renal, breast
  • Cushing syndrome ACTH Small cell lung
  • SIADH ADH Small cell lung
  • Polycythemia EPO RCC, HCC, hemangioblastoma
  • Lambert-Eaton Antibodies to presynaptic Ca2+ channels Small cell lung
  • Myasthenia-like / dermatomyositis Autoimmune Thymoma; various adenocarcinomas
  • Carcinoid syndrome Serotonin Metastatic neuroendocrine (liver)
  • Acanthosis nigricans / Trousseau Various Gastric, pancreatic (migratory thrombophlebitis)

Cachexia is progressive wasting of fat and muscle out of proportion to simple starvation, driven by TNF-α (cachectin) , IL-1, IL-6, and IFN-γ altering metabolism and appetite. It is a major cause of morbidity in advanced cancer and chronic inflammatory disease.

Integration for CBSE Vignettes

Approach: name the process (benign vs malignant; dysplasia vs invasion), then map the molecular hit if given a translocation or inherited syndrome, then use markers/paraneoplastics as tie-breakers. A young patient with countless colon polyps → APC/FAP. MSI colon cancer without polyposis → Lynch/MMR. t(9;22) leukocytosis → BCR-ABL. Squamous lung cancer + high calcium → PTHrP. That layered logic is how multisystem neoplasia items are written.